雷珠单抗治疗糖尿病性黄斑水肿
Ranibizumab in diabetic macular edema.
作者信息
Krispel Claudia, Rodrigues Murilo, Xin Xiaoban, Sodhi Akrit
机构信息
Claudia Krispel, Murilo Rodrigues, Xiaoban Xin, Akrit Sodhi, Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, MD 21287, United States.
出版信息
World J Diabetes. 2013 Dec 15;4(6):310-8. doi: 10.4239/wjd.v4.i6.310.
Abstract
By 2050 the prevalence of diabetes will more than triple globally, dramatically increasing the societal and financial burden of this disease worldwide. As a consequence of this growth, it is anticipated that there will be a concurrent rise in the numbers of patients with diabetic macular edema (DME), already among the most common causes of severe vision loss worldwide. Recent available therapies for DME target the secreted cytokine, vascular endothelial growth factor (VEGF). This review focuses on the treatment of DME using the first humanized monoclonal antibody targeting VEGF that has been Food and Drug Administration-approved for the use in the eye, ranibizumab (Lucentis(®)).
摘要
到2050年，全球糖尿病患病率将增长两倍多，极大地增加这种疾病在全球范围内的社会和经济负担。由于这种增长，预计糖尿病性黄斑水肿（DME）患者数量也将同时增加，DME已是全球严重视力丧失的最常见原因之一。最近可用的DME治疗方法以分泌的细胞因子血管内皮生长因子（VEGF）为靶点。本综述重点介绍使用首个被美国食品药品监督管理局批准用于眼部的靶向VEGF的人源化单克隆抗体雷珠单抗（Lucentis®）治疗DME。
相似文献
1
Ranibizumab in diabetic macular edema.雷珠单抗治疗糖尿病性黄斑水肿
World J Diabetes. 2013 Dec 15;4(6):310-8. doi: 10.4239/wjd.v4.i6.310.
2
Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.难治性糖尿病性黄斑水肿的治疗策略：更换抗血管内皮生长因子（anti-VEGF）治疗、采用基于皮质类固醇的治疗以及联合治疗。
Expert Opin Biol Ther. 2016;16(3):365-74. doi: 10.1517/14712598.2016.1131265. Epub 2016 Jan 12.
3
Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.玻璃体内雷珠单抗与阿柏西普和贝伐珠单抗治疗视网膜中央静脉阻塞所致黄斑水肿的比较：LEAVO 非劣效性三臂 RCT。
Health Technol Assess. 2021 Jun;25(38):1-196. doi: 10.3310/hta25380.
4
The Role of Anti-VEGF Therapy in the Treatment of Diabetic Macular Edema.抗血管内皮生长因子疗法在糖尿病性黄斑水肿治疗中的作用
Ophthalmic Surg Lasers Imaging Retina. 2016 Jun;47(6 Suppl):S4-S14. doi: 10.3928/23258160-20160415-01.
5
[Intravitreal ranibizumab in diabetic macular edema].玻璃体内注射雷珠单抗治疗糖尿病性黄斑水肿
Klin Oczna. 2010;112(10-12):333-6.
6
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.血管内皮生长因子在年龄相关性黄斑变性和糖尿病性黄斑水肿患者玻璃体内注射贝伐单抗、雷珠单抗和聚乙二醇化阿柏西普前后的血浆水平。
Br J Ophthalmol. 2013 Apr;97(4):454-9. doi: 10.1136/bjophthalmol-2012-302451. Epub 2013 Feb 5.
7
CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.玻璃体腔内注射贝伐单抗、阿柏西普或雷珠单抗治疗糖尿病性黄斑水肿后血浆血管内皮生长因子水平的变化。
Retina. 2018 Sep;38(9):1801-1808. doi: 10.1097/IAE.0000000000002004.
8
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.玻璃体内注射阿柏西普、贝伐单抗或雷珠单抗治疗伴有视力损害的累及中心的糖尿病性黄斑水肿后持续性黄斑增厚：一项随机临床试验的二次分析。
JAMA Ophthalmol. 2018 Mar 1;136(3):257-269. doi: 10.1001/jamaophthalmol.2017.6565.
9
The efficacy of micropulse laser combined with ranibizumab in diabetic macular edema treatment: study protocol for a randomized controlled trial.微脉冲激光联合雷珠单抗治疗糖尿病黄斑水肿的疗效：一项随机对照试验的研究方案。
Trials. 2022 Sep 2;23(1):736. doi: 10.1186/s13063-022-06593-2.
10
Current intravitreal pharmacologic therapies for diabetic macular edema.目前用于治疗糖尿病性黄斑水肿的玻璃体内药物疗法。
Postgrad Med. 2015 Aug;127(6):640-53. doi: 10.1080/00325481.2015.1052523. Epub 2015 Jun 3.
引用本文的文献
1
Solution-Phase Kinetics of Ranibizumab Binding VEGF Using Solid-Phase Surface Plasmon Resonance.使用固相表面等离子体共振技术研究雷珠单抗结合血管内皮生长因子的溶液相动力学
Anal Chem. 2025 Mar 25;97(11):6027-6033. doi: 10.1021/acs.analchem.4c06023. Epub 2025 Mar 17.
2
C176-loaded and phosphatidylserine-modified nanoparticles treat retinal neovascularization by promoting M2 macrophage polarization.载有C176且经磷脂酰丝氨酸修饰的纳米颗粒通过促进M2巨噬细胞极化来治疗视网膜新生血管形成。
Bioact Mater. 2024 May 28;39:392-405. doi: 10.1016/j.bioactmat.2024.05.038. eCollection 2024 Sep.
3
Targeting hypoxia-inducible factors with 32-134D safely and effectively treats diabetic eye disease in mice.用 32-134D 靶向缺氧诱导因子安全有效地治疗小鼠的糖尿病眼病。
J Clin Invest. 2023 Jul 3;133(13):e163290. doi: 10.1172/JCI163290.
4
Aflibercept versus ranibizumab for diabetic macular edema: A meta-analysis.阿柏西普与雷珠单抗治疗糖尿病性黄斑水肿的荟萃分析。
Eur J Ophthalmol. 2024 May;34(3):615-623. doi: 10.1177/11206721231178658. Epub 2023 May 24.
5
HIF-1α accumulation in response to transient hypoglycemia may worsen diabetic eye disease.短暂性低血糖反应导致 HIF-1α 堆积可能使糖尿病眼病恶化。
Cell Rep. 2023 Jan 31;42(1):111976. doi: 10.1016/j.celrep.2022.111976. Epub 2023 Jan 10.
6
Expression of functional eGFP-fused antigen-binding fragment of ranibizumab in .雷珠单抗功能性eGFP融合抗原结合片段在……中的表达
Bioimpacts. 2022;12(3):203-210. doi: 10.34172/bi.2021.23219. Epub 2021 Oct 11.
7
HIF-1α and HIF-2α redundantly promote retinal neovascularization in patients with ischemic retinal disease.缺氧诱导因子-1α（HIF-1α）和缺氧诱导因子-2α（HIF-2α）在缺血性视网膜疾病患者中冗余性促进视网膜新生血管形成。
J Clin Invest. 2021 Jun 15;131(12). doi: 10.1172/JCI139202.
8
Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients.约旦患者队列中影响糖尿病性黄斑水肿抗血管内皮生长因子治疗依从性的因素
Clin Ophthalmol. 2020 Mar 24;14:921-929. doi: 10.2147/OPTH.S248661. eCollection 2020.
9
Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema.血管生成素样蛋白 4 结合神经纤毛蛋白并与 VEGF 协同诱导糖尿病性黄斑水肿。
J Clin Invest. 2019 Nov 1;129(11):4593-4608. doi: 10.1172/JCI120879.
10
Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections.玻璃体内注射抗VEGF药物治疗糖尿病性黄斑水肿时黄斑收缩及玻璃体视网膜界面改变的定量评估
Graefes Arch Clin Exp Ophthalmol. 2018 Oct;256(10):1801-1806. doi: 10.1007/s00417-018-4042-5. Epub 2018 Jun 20.
本文引用的文献
1
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results.雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性：两年结果。
Ophthalmology. 2020 Apr;127(4S):S135-S145. doi: 10.1016/j.ophtha.2020.01.029.
2
Vascular endothelial growth factor a in intraocular vascular disease.血管内皮生长因子 A 与眼内血管疾病。
Ophthalmology. 2013 Jan;120(1):106-14. doi: 10.1016/j.ophtha.2012.07.038. Epub 2012 Sep 29.
3
Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.玻璃体腔内雷珠单抗治疗糖尿病黄斑水肿：即刻与延迟激光治疗的 3 年随机试验结果。
Ophthalmology. 2012 Nov;119(11):2312-8. doi: 10.1016/j.ophtha.2012.08.022. Epub 2012 Sep 19.
4
Long-term effects of ranibizumab on diabetic retinopathy severity and progression.雷珠单抗对糖尿病性视网膜病变严重程度和进展的长期影响。
Arch Ophthalmol. 2012 Sep;130(9):1145-52. doi: 10.1001/archophthalmol.2012.1043.
5
A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.一项为期2年的玻璃体腔内注射贝伐单抗或激光治疗（BOLT）糖尿病性黄斑水肿的前瞻性随机对照试验：24个月数据：报告3
Arch Ophthalmol. 2012 Aug;130(8):972-9. doi: 10.1001/archophthalmol.2012.393.
6
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.雷珠单抗治疗糖尿病性黄斑水肿：两项 III 期随机临床试验（RISE 和 RIDE）的结果。
Ophthalmology. 2012 Apr;119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039. Epub 2012 Feb 11.
7
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.VEGF 陷阱、雷珠单抗和贝伐珠单抗与血管内皮生长因子（VEGF）及其相关配体的结合和中和作用。
Angiogenesis. 2012 Jun;15(2):171-85. doi: 10.1007/s10456-011-9249-6.
8
Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?黄斑缺血：视网膜血管疾病抗 VEGF 治疗的禁忌证？
Br J Ophthalmol. 2012 Feb;96(2):179-84. doi: 10.1136/bjophthalmol-2011-301087.
9
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians.眼内抗血管内皮生长因子疗法的发展：临床医生指南
J Ophthalmol. 2012;2012:483034. doi: 10.1155/2012/483034. Epub 2011 Dec 18.
10
The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.DA VINCI 研究：抗 VEGF 陷阱眼在糖尿病黄斑水肿患者中的 2 期主要结果。
Ophthalmology. 2011 Sep;118(9):1819-26. doi: 10.1016/j.ophtha.2011.02.018. Epub 2011 May 5.
Zotero 插件